Taub Rebecca’s SEC Form 4 activity paints a picture of consistent, large-scale divestment from a single holding: Madrigal Pharmaceuticals (MDGL). Across 71 reported transactions, the insider has recorded zero open-market purchases and zero acquisitions, while total sales have reached approximately $48.1 million. The recent window is particularly active, with 22 sell-side transactions clustered heavily on January 9, 2026, alongside a smaller sale on March 6, 2026. The January 9 cluster alone shows a rapid-fire series of sales ranging from roughly $15,900 to over $1.09 million, with individual transactions spread across the day, suggesting a methodical liquidation of a substantial position.
The selling bias is unambiguous. The most recent open-market sale occurred on March 6, 2026, at a value of $212,082.54, following a January 26 sale of $318,595.74 and a January 20 sale of $1,098,343.26. The bulk of the activity, however, is concentrated in the January 9 block, which includes more than a dozen sales totaling several million dollars. Notably, this selling is accompanied by a single option exercise (code "M") on the same date, valued at just $3,792—a mechanical transaction that typically precedes a sale of the underlying shares. Two grants (code "A") on June 17, 2026, carry a zero dollar value, indicating compensation awards rather than market purchases.
The pattern reveals a clear directional trend: Taub Rebecca is a net seller of MDGL, with no appetite for accumulating additional shares in the open market. The absence of any purchase activity, combined with the sheer volume of sales—particularly the high-frequency, high-value disposals in early January—signals a sustained reduction in exposure to the company. While the transactions are routine in their mechanics, the scale and timing suggest an insider actively unwinding a position, with the most recent data showing no reversal of that trajectory.
AI-assisted summary